TrialPloS one2024

A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.

Ian R Woodcock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.